Drug Profile
Angiotensin-II receptor antibody - Materia Medica Holding
Alternative Names: CardostenLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Materia Medica Holding Research and Production Company
- Developer Materia Medica Holdings
- Class Antibodies; Heart failure therapies
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Heart-failure in Russia (PO, Tablet)
- 31 Aug 2011 Clinical trials in Heart failure in Russia (PO)
- 31 Aug 2011 Efficacy data from a Clinical trial in Heart failure released by Materia Medica Holding Research and Production Company